Go Pro
NASDAQ:IART

Integra LifeSciences (IART) Stock Price, News & Analysis

Integra LifeSciences logo
$17.07 -0.18 (-1.04%)
As of 04:00 PM Eastern

About Integra LifeSciences Stock (NASDAQ:IART)

Advanced

Key Stats

Today's Range
$17.00
$17.52
50-Day Range
$15.67
$19.85
52-Week Range
$8.70
$20.49
Volume
686,198 shs
Average Volume
907,390 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.86
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts. Key additions to its portfolio include the integration of Derma Sciences’ regenerative wound care products and the acquisition of Johnson & Johnson’s Codman neurosurgery business. These strategic moves have broadened the company’s offerings across dura repair, nerve regeneration and orthopedic extremities.

Integra’s technologies serve a diverse set of clinical settings, including hospitals, outpatient surgical centers and specialty clinics. With a presence in North America, Europe, Asia-Pacific and Latin America, the company maintains manufacturing and distribution operations on multiple continents to support regional product demand and regulatory compliance. Its global footprint allows for collaboration with healthcare professionals on product development and clinical training initiatives.

The company is guided by a management team with extensive experience in medical device innovation, regulatory affairs and commercial operations. Integra continues to invest in research and development, pursuing new applications in tissue engineering and minimally invasive surgery while maintaining a focus on improving patient outcomes and supporting healthcare providers worldwide.

AI Generated. May Contain Errors.

Integra LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 606th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, 1 buy rating, 5 hold ratings, and 2 sell ratings.

  • Upside Potential

    Integra LifeSciences has a consensus price target of $18.86, representing about 10.2% upside from its current price of $17.11.

  • Amount of Analyst Coverage

    Integra LifeSciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 4.07% in the coming year, from $2.46 to $2.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is -190.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is -190.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Integra LifeSciences has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Integra LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.29% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 7.17.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 2.96%, indicating that investor sentiment is improving.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • News Sentiment

    Integra LifeSciences has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Integra LifeSciences this week, compared to 4 articles on an average week.
  • Search Interest

    3 people have searched for IART on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.84% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IART Stock News Headlines

Integra (IART) Q2 2026 Earnings Call Transcript
Bernie is gunning for your money
Bernie Sanders introduced a bill proposing a one-time 50% tax on shares of America's most successful companies - not on profits or revenue, but on the equity itself. Trump has now backed the same sovereign wealth fund concept, and the U.S. government already owns stakes in 37 companies worth $27.6 billion. A Silicon Valley doctrine may be behind the push, redirecting capital at massive scale toward a small group of firms.tc pixel
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $12.42 at the beginning of the year. Since then, IART shares have increased by 37.8% and is now trading at $17.11.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) released its earnings results on Wednesday, July, 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.08. The life sciences company earned $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive trailing twelve-month return on equity of 18.30%.
Read the conference call transcript
.

Shares of Integra LifeSciences split on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences subsidiaries include these companies: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Top institutional investors of Integra LifeSciences include Bank of New York Mellon Corp (0.62%) and Assenagon Asset Management S.A. (0.18%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen and Jeffrey A Graves.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
7/29/2026
Today
8/10/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:IART
CIK
917520
Employees
4,427
Year Founded
1989

Price Target and Rating

High Price Target
$25.00
Low Price Target
$13.00
Potential Upside/Downside
+10.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.94
P/E Growth
1.45
Net Income
-$516.47 million
Net Margins
-0.44%
Pretax Margin
-0.01%
Return on Equity
18.30%
Return on Assets
5.30%

Debt

Debt-to-Equity Ratio
1.75
Current Ratio
3.60
Quick Ratio
2.11

Sales & Book Value

Annual Sales
$1.64 billion
Price / Sales
0.81
Cash Flow
$4.17 per share
Price / Cash Flow
4.09
Book Value
$13.40 per share
Price / Book
1.27

Miscellaneous

Outstanding Shares
77,770,000
Free Float
74,787,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
1.21

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:IART) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners